MAPT and tauopathy: Given the evidence implicating soluble tau oligomers in the molecular pathogenesis of tauopathies, these data suggest that targeting LCMT‐1 or PME‐1 may be viable approaches to ameliorating the impairments caused by soluble tau oligomers in these disorders.75, 76, 77